Can a daily pill stop keloids from coming back?

NCT ID NCT06373458

Recruiting now Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug ritlecitinib can prevent keloids from returning after surgical removal. Keloids are raised, often itchy scars that grow beyond the original wound. The trial will enroll 30 adults who will take a daily pill for 36 weeks. Researchers will measure keloid recurrence and severity using a special scale and a skin hardness device.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ritlecitinib (a JAK inhibitor drug taken as a daily pill)
What this could lead to: If successful, this could point toward a new treatment option that reduces keloid recurrence and severity after surgery.
What could go wrong: This is a small, early-phase (2a) trial with only 30 participants, so results may not apply to everyone. The drug may not work better than existing treatments, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KELOID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

keloid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KELOID

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.